The addictive properties of narcotic analgesices result in widespread drug abuse and are undesirable side-effects of their use in the treatment of pain. Despite the importance of opioid drugs, our knowledge of the mechanisms underlying their addictive properties remains unclear. Activation of the mu opioid receptor is a necessary first step in producting opioid analgesia and other acute pharmacological effects, but it also appears to initiate a series of more poorly defined chronic changes associated with addiction. In this project we will address the following questions: What signaling pathways of the mu receptor are responsible for the acute and chronic effects of narcotic analgesics? Are these pathways distinct, and which ones are involved in regulating tolerance and dependence, two of the main questions in the following way: """"""""First: we propose that mu receptors have basal activity--signaling activity in the absence of agonist--and that this basal activity increases after prolonged agonist treatment. Increased basal activity may represent a sensitization process. In contrast, agonist-dependent stimulation of mu receptor signaling is known to desensitize. Both the enhanced basal activity and the blunted agonist response could contribute to tolerance and dependence. We propose that differential phosphorylation of the mu receptor plays a role in this dual regulation, leading to both sensitization and desensitization. Second, based on recently obtained evidence we propose that calmodulin binds directly to the third intracellular loop pf mu opioid receptors. This is the first example of a direct interaction of calmodulin with a G protein coupled receptor. We will study the possible role of Ca2+ and calmodulin in reguling G protein coupling and phosphorylation of the mu opioid receptor. On the other hand, calmodulin could also serve as an alternate second messenger of mu receptor signaling per se, contributing to chronic adaptations associated with addiction. Third, we propose that the mu receptor exists in multiple conformation or functional states. This may result in varying ligand binding affinities and second messenger coupling. In addition to G protein coupling, we will examine activation of Ca++ influx and calmodulin as alternative signaling pathways of the mu opioid receptor. To test this hypothesis, we will screen a panel of opioid drugs and peptides for ability to stimulate these multiple signaling pathways. Further, we will test the hypothesis that the observed differential agonist effects could result from receptor aggregation into signaling complexes with effector proteins, such as calcium channels. Considered together, these hypotheses may yield important insights into the mechanisms underlying tolerance and dependence, providing the opportunity to develop effective therapies of narcotic addiction.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
7R01DA004166-15
Application #
6515385
Study Section
Special Emphasis Panel (ZRG1-MDCN-5 (01))
Program Officer
Lin, Geraline
Project Start
1986-08-01
Project End
2004-03-31
Budget Start
2002-04-02
Budget End
2003-03-31
Support Year
15
Fiscal Year
2002
Total Cost
$189,007
Indirect Cost
Name
Ohio State University
Department
Pharmacology
Type
Schools of Medicine
DUNS #
098987217
City
Columbus
State
OH
Country
United States
Zip Code
43210
Wang, Danxin; Sun, Xiaochun; Sadee, Wolfgang (2007) Different effects of opioid antagonists on mu-, delta-, and kappa-opioid receptors with and without agonist pretreatment. J Pharmacol Exp Ther 321:544-52
Lucas, Julie L; Wang, Danxin; Sadee, Wolfgang (2006) Calmodulin binding to peptides derived from the i3 loop of muscarinic receptors. Pharm Res 23:647-53
Zhang, Ying; Wang, Danxin; Sadee, Wolfgang (2005) Calmodulin interaction with peptides from G-protein coupled receptors measured with S-Tag labeling. Biochem Biophys Res Commun 333:390-5
Sadee, Wolfgang; Wang, Danxin; Bilsky, Edward J (2005) Basal opioid receptor activity, neutral antagonists, and therapeutic opportunities. Life Sci 76:1427-37
Wang, Danxin; Sun, Xiaochun; Bohn, Laura M et al. (2005) Opioid receptor homo- and heterodimerization in living cells by quantitative bioluminescence resonance energy transfer. Mol Pharmacol 67:2173-84
Raehal, Kirsten M; Lowery, John J; Bhamidipati, Castigliano M et al. (2005) In vivo characterization of 6beta-naltrexol, an opioid ligand with less inverse agonist activity compared with naltrexone and naloxone in opioid-dependent mice. J Pharmacol Exp Ther 313:1150-62
Wang, Danxin; Raehal, Kirsten M; Lin, Emil T et al. (2004) Basal signaling activity of mu opioid receptor in mouse brain: role in narcotic dependence. J Pharmacol Exp Ther 308:512-20
Quillan, J Mark; Carlson, Kurt W; Song, Chunyan et al. (2002) Differential effects of mu-opioid receptor ligands on Ca(2+) signaling. J Pharmacol Exp Ther 302:1002-12
Lin, Kedan; Wang, Danxin; Sadee, Wolfgang (2002) Serum response factor activation by muscarinic receptors via RhoA. Novel pathway specific to M1 subtype involving calmodulin, calcineurin, and Pyk2. J Biol Chem 277:40789-98
Wang, D; Raehal, K M; Bilsky, E J et al. (2001) Inverse agonists and neutral antagonists at mu opioid receptor (MOR): possible role of basal receptor signaling in narcotic dependence. J Neurochem 77:1590-600

Showing the most recent 10 out of 45 publications